Request Appointment
161 Fort Washington AveNew York, NY 10032
Overview of Dr. Manji
Dr. Gulam Manji is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Ross University School of Medicine and has been in practice 8 years. He is one of 372 doctors at New York-Presbyterian Hospital and one of 121 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 40 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
Albany Medical CenterResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009
Certifications & Licensure
OH State Medical License 2024 - 2026
NY State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2015 Nov 04
- Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Start of enrollment: 2019 Nov 01
Publications & Presentations
PubMed
- Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.Karie Runcie, Yadriel Bracero, Avishai Samouha, Gulam Manji, Helen E Remotti
The Oncologist. 2025-01-17 - Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue.Michael S May, Heekuk Park, Dalia H Moallem, Dwayne Seeram, Sun Dajiang
International Journal of Molecular Sciences. 2024-12-27 - Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy.Alexander S Thomas, Parisa Tehranifar, Wooil Kwon, Nupur Shridhar, Kazuki N Sugahara
Journal of Surgical Oncology. 2024-12-01
Press Mentions
- Researchers Discover How Pancreatic Cancer Cells Evade StarvationNovember 3rd, 2020
- BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic CancerOctober 29th, 2020
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 29th, 2024- Join now to see all
Grant Support
- Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
- Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
- Elucidation and targeting of paracrine cascades in PDACCOLUMBIA UNIVERSITY HEALTH SCIENCES2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
